HYDI Hydromer Inc.

Hydromer as the Exclusive Coatings Partner for N8 Announces the CeraShield Coating Has Demonstrated the Ability to Inhibit and Reduce the Growth of COVID-19 Virus on Tube Surfaces

Hydromer as the Exclusive Coatings Partner for N8 Announces the CeraShield Coating Has Demonstrated the Ability to Inhibit and Reduce the Growth of COVID-19 Virus on Tube Surfaces

Concord, NC, Aug. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hydromer Incorporated (OTC:HYDI) or “the Company” announced today, as the exclusive coatings supplier and manufacturing partner for N8 Medical’s CeraShield™ coated endotracheal tubes, that the CeraShield™ coating has in recent testing demonstrated the ability to inhibit and reduce the growth of COVID-19 virus on tube surfaces. The testing showed statistically significant reduction in the growth of COVID-19 virus on the tube surface in 60 minutes. Ordinary uncoated endotracheal tubes either allowed increased virus growth or had no inhibitory effect. A clinical study is being planned by N8 Medical’s team.

Ronald Bracken, President and Chief Operating Officer of N8 Medical, said, “Recent COVID-19 research has shown that the virus is able to adhere to plastic surfaces for days and is also able to be aerosolized and inhaled by people in close proximity, including doctors and nurses.” He also added, “COVID-19 patients who become mechanically ventilated will require use of one of plastic endotracheal tubes to connect to the mechanical ventilator, so reducing virus growth on them could provide a meaningful benefit.”

“Hydromer is very proud to be aligned with N8 Medical and views this new data as promising and highly relevant, given the global pandemic,” said Peter M. von Dyck, Chief Executive Officer of Hydromer.

CAUTION: In United States, the CeraShield™ Endotracheal Tube has not been granted marketing approval. These statements have not been evaluated by Health Canada or FDA.

About Hydromer®

is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs.

Nikki Barnes

800-208-0314

EN
18/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hydromer Inc.

 PRESS RELEASE

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Thi...

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 CONCORD, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC: HYDI) (the “Company”), a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce certain preliminary, unaudited management-prepared financial results for the quarter ended September 30, 2024. These results are based on the most current information available to management, are unaudited, and are subject to the completion of the Company’s 2024 year-end ...

 PRESS RELEASE

Hydromer, Inc. Announces the Restructuring and Formation of World-Clas...

Hydromer, Inc. Announces the Restructuring and Formation of World-Class Research and Development Division to Drive Innovation and New Product Development ·       Company introduces a top-tier team of chemists to lead innovation in hydrophilic coatings and develop cutting-edge, environmentally friendly solutions ·       Restructured R&D division, under new leadership, aims to enhance product offerings, improve operational efficiency, and drive future growth CONCORD, N.C. , Oct. 21, 2024 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC: HYDI), a leader in hydrophilic coating technologie...

 PRESS RELEASE

Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Fin...

Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update CONCORD, NC, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC: HYDI) (the “Company”), a leader in hydrophilic, thromboresistant and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce certain Corporate Highlights and preliminary, unaudited management-prepared financial results for the quarter ended June 30, 2024. These results are based on the most current information available to management, are unaudited and are subject to ch...

 PRESS RELEASE

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Fir...

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 CONCORD, NC, April 29, 2024 (GLOBE NEWSWIRE) -- via -- Hydromer, Inc. (OTC: HYDI) (the “Company”), a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce certain preliminary, unaudited management-prepared financial results for the quarter ended March 31, 2024. These results are based on the most current information available to management, are unaudited, and are subject to the completion of the Company’s 2024 year-en...

 PRESS RELEASE

Hydromer, Inc. Wraps Up a Successful 2023, Including Restructuring, Co...

Hydromer, Inc. Wraps Up a Successful 2023, Including Restructuring, Contract Extensions, and the Launch of New Innovations CONCORD, NC, Jan. 16, 2024 (GLOBE NEWSWIRE) -- via – Hydromer, Inc. (OTC: HYDI) Hydromer, Inc. (the “Company”) is pleased to provide the following update to shareholders regarding the Company’s progress toward stability and profitable growth. Much has been done since the spring of 2023 in reducing the Company’s overhead and operating costs, which management believes will lead to improved profitability in the current fiscal year. Additionally, investment in new prod...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch